Disease or Syndrome
RyCarma Therapeutics Unveils New Leadership and Company Name, Expands Focus on Heart Failure Treatment
RyCarma Therapeutics, ARMGO Pharma, ryanodine receptor, Rycals, heart failure, cardiovascular diseases, skeletal muscle diseases, biotech company, new leadership, company name change.
Servier and Google Cloud Extend Partnership to Accelerate AI-Powered Drug Development
Servier, Google Cloud, AI, drug development, pharmaceutical research, digital transformation, R&D, generative AI, gen AI, therapeutic solutions.
Appeals Court Upholds FDA’s Denial of Fast Track Designation for Vanda’s Gastroparesis Drug
FDA, Vanda Pharmaceuticals, Fast Track Designation, Gastroparesis, Drug Approval Process
FDA Approves Lilly’s Omvoh for Crohn’s Disease, Expanding Treatment Options
Omvoh, FDA approval, Crohn’s disease, inflammatory bowel disease, mirikizumab-mrkz, Eli Lilly
NVIDIA’s AI Innovations: Pioneering the Future of Artificial Intelligence
NVIDIA AI Innovations, Generative AI, Accelerated Computing, Robotics, AI in Healthcare, AI Foundation Models
Hinge Bio Secures $30 Million Series A’ Financing for Next-Generation Therapies via GEM-DIMER Platform
Hinge Bio, immune reset, GEM-DIMER platform, Series A’ financing, autoimmune diseases, HB2198, Systemic Lupus Erythematosus
GSK Advances Liver Disease Research and Biotech CEO Sisterhood Grows Influence
GSK, liver disease, Biotech CEO Sisterhood, JPM25, pharmaceutical industry, women in biotech
GE HealthCare and UCSF Launch ‘Care Innovation Hub’ to Revolutionize Medical Imaging for Cancer and Neurodegenerative Diseases
GE HealthCare, UCSF, Care Innovation Hub, medical imaging, cancer, neurodegenerative diseases, precision oncology, brain health, automated imaging techniques, MRI, radiopharmaceutical therapies.
RegenXBio Secures $110M Upfront in Strategic Partnership with Nippon Shinyaku for Hunter Syndrome Gene Therapy
RegenXBio, Hunter syndrome, Gene therapy, Nippon Shinyaku, Strategic partnership, Rare metabolic disorder, Mucopolysaccharidosis type II (MPS II), RGX-121, RGX-111
BridgeBio Pharma Reports Strong Commercial Progress and Pipeline Updates for 2025
BridgeBio Pharma, Attruby, commercial progress, pipeline updates, 2025 milestones, rare genetic diseases, Phase 3 clinical trials, FORTIFY, CALIBRATE, PROPEL 3.